Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
MN

NASDAQ · MNOV

MediciNova, Inc.

Healthcare · Biotechnology

$1.79

Down-$0.05 (-2.79%)

Updated Sep 11, 2026, 12:38 AM

SID Score

5.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
74.55M
P/E ratio
-6.31
Dividend yield
0.00%
52-week range
$1.22 – $1.85
Volume
106.28K
Avg. volume
972.45K

Price performance

MNOV price history

1M range · 19 trading sessions · Daily adjusted prices

MNOV closed at $1.79 after 19 trading sessions, up 36.64% for the selected period.

Last close
$1.79
Period change
+36.64%
Period low
$1.31
Period high
$1.79
Daily close
View OHLC price history
MNOV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$1.82$1.848$1.75$1.79106.28K
Sep 8, 2026$1.67$1.755$1.652$1.75138.41K
Sep 4, 2026$1.62$1.63$1.55$1.6396.72K
Sep 3, 2026$1.45$1.63$1.45$1.62111.26K
Sep 2, 2026$1.44$1.4577$1.43$1.4314.3K
Sep 1, 2026$1.46$1.46$1.42$1.4419.97K
Aug 31, 2026$1.43$1.4644$1.43$1.43518.67K
Aug 28, 2026$1.42$1.4488$1.42$1.43516.89K
Aug 27, 2026$1.49$1.52$1.42$1.4225.44K
Aug 26, 2026$1.57$1.58$1.43$1.4840.7K
Aug 25, 2026$1.55$1.58$1.48$1.5787.13K
Aug 24, 2026$1.39$1.54$1.39$1.53118.9K
Aug 21, 2026$1.38$1.40$1.3701$1.3926.06K
Aug 20, 2026$1.38$1.38$1.325$1.3724.41K
Aug 19, 2026$1.35$1.39$1.35$1.3856K
Aug 18, 2026$1.325$1.35$1.3201$1.3448.02K
Aug 17, 2026$1.32$1.34$1.3011$1.3267.36K
Aug 14, 2026$1.32$1.33$1.3001$1.3145.06K
Aug 13, 2026$1.32$1.3201$1.31$1.3122.16K

Latest MNOV news

The latest Smart Investors Daily articles mentioning MNOV.

Stock researchCompany · Overview

MNOV research

Overview

Company profile and research snapshot.

Company profile

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
MNOV recent ratings
DateFirmRatingTarget
May 4, 2026D. Boral CapitalBuy—
Mar 23, 2026Maxim GroupBuy—
Mar 16, 2026HC Wainwright & Co.Buy—
Jan 30, 2026D. Boral CapitalBuy—
Dec 18, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

MediciNova to Participate in Two Investor Conferences in September

LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, will participate in two investor conferences during September. H.C. Wainwright 28th Annual Global Investment Conference, September 14-16 at the Lotte

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By